Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)

S. Cytryn, S. Joshi,G. Y. Ku,S. B. Maron, A. Desai,J. Yang, D. Rao, Z. Goldberg, R. Sugarman, A. Antoine, F. Socolow,J. F. Chou,M. Capanu,H. Gerdes, M. Simmons,V. Paroder,L. Tang,J. Shia,D. H. Ilson,Y. Y. Janjigian

ANNALS OF ONCOLOGY（2022）

Cited 0|Views0

No score

Abstract

NIVO plus chemotherapy demonstrated superior overall survival (OS) versus chemotherapy in metastatic EGC (Janjigian et al, Lancet 2021). We report preliminary results of a single center investigator initiated phase II study of first-line REGO with NIVO and FOLFOX in this population.

Translated text

Key words

negative esophagogastric cancer,1227p regorafenib,nivolumab

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined